The tariff classification of G2-W Singulator from Costa Rica.
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Ruling text
In your letter dated February 13, 2026, you requested a tariff classification ruling on behalf of your client, Glaukos Corporation. You state Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The item in consideration is the G2-W Singulator, a specifically designed component of the iStent inject W Trabecular Micro-Bypass System.
The G2-W Singulator is an internal, non-implantable mechanical component of the system that advances and deploys the trabecular micro-bypass stent. It is made of nickel-titanium alloy and housed inside the distal micro-insertion tube of the injector. Its sole function is to mechanically push the preloaded stent into the patient’s trabecular meshwork; the stent itself is not contained within the singulator.
During use, the singulator advances forward, pushing the stent from behind out of the micro insertion tube and into position. The G2-W Singulator does not cut tissue, transport fluids or remain implanted in the patient; it is discarded after the procedure. The iStent inject W Trabecular Micro-Bypass System consists of an injector and two trabecular bypass stents, which are implanted into the trabecular meshwork in patients with documented glaucomatous optic neuropathy.
The system is intended for use in conjunction with cataract surgery in adult patients with mild to moderate primary open-angle glaucoma. Its primary medical purpose is to lower intraocular pressure, reduce mechanical and ischemic stress on the optic nerve, slow or halt progressive visual loss, and reduce reliance on chronic medications. The system is not designed, approved, or marketed for unrelated ophthalmic procedures or for implantations in individuals without established glaucoma.
The iStent inject W Trabecular Mirco-Bypass System helps mitigate the progression of permanent visual impairment in patients with mild to moderate glaucoma. As you noted, patients at these stages already have an existing chronic visual impairment, with documented optic nerve damage and measurable visual field impairment confirmed through clinical evaluation at the time of implantation. Lost vision cannot be restored, and disease progression continues without intervention.
Peripheral visual field loss directly affects driving, navigation, reading, occupational performance, and independent living. Therefore, glaucoma significantly affects the major life activity of seeing.
The applicable subheading for G2-W Singulator will be 9018.50.0000, HTSUS, which provides for “]i]nstruments and appliances used in medical, surgical, dental or veterinary sciences, including scintigraphy apparatus, other electro-medical apparatus and sight-testing instruments; parts and accessories thereof: [o]ther ophthalmic instruments and appliances and parts and accessories thereof.” The general rate of duty will be free.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N358892).